Human Umbilical Cord-derived Mesenchymal Stromal Cells Ameliorate Aging-associated Skeletal Muscle Atrophy and Dysfunction by Modulating Apoptosis and Mitochondrial Damage in SAMP10 Mice
Overview
Affiliations
Background: Skeletal muscle mass and function losses in aging individuals are associated with quality of life deterioration and disability. Mesenchymal stromal cells exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in aging-related degenerative disease.
Methods And Results: We investigated the efficacy of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) on sarcopenia-related skeletal muscle atrophy and dysfunction in senescence-accelerated mouse prone 10 (SAMP10) mice. We randomly assigned 24-week-old male SAMP10 mice to a UC-MSC treatment group and control group. At 12 weeks post-injection, the UC-MSC treatment had ameliorated sarcopenia-related muscle changes in performance, morphological structures, and mitochondria biogenesis, and it enhanced the amounts of proteins or mRNAs for myosin heavy chain, phospho-AMP-activated protein kinase, phospho-mammalian target of rapamycin, phospho-extracellular signal-regulated kinase1/2, peroxisome proliferator-activated receptor-γ coactivator, GLUT-4, COX-IV, and hepatocyte growth factor in both gastrocnemius and soleus muscles, and it reduced the levels of proteins or mRNAs for cathepsin K, cleaved caspase-3/-8, tumor necrosis factor-α, monocyte chemoattractant protein-1, and gp91 mRNAs. The UC-MSC treatment retarded mitochondria damage, cell apoptosis, and macrophage infiltrations, and it enhanced desmin/laminin expression and proliferating and CD34/Integrin α cells in both types of skeletal muscle of the SAMP10 mice. In vitro, we observed increased levels of HGF, PAX-7, and MoyD mRNAs at the 4th passage of UC-MSCs.
Conclusions: Our results suggest that UC-MSCs can improve sarcopenia-related skeletal muscle atrophy and dysfunction via anti-apoptosis, anti-inflammatory, and mitochondrial biogenesis mechanisms that might be mediated by an AMPK-PGC1-α axis, indicating that UC-MSCs may provide a promising treatment for sarcopenia/muscle diseases.
Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy.
Wang Y, Chen Z, Shen Y, Wang K, Han Y, Zhang C World J Stem Cells. 2025; 17(2):98693.
PMID: 40061264 PMC: 11885941. DOI: 10.4252/wjsc.v17.i2.98693.
Song J, Yang M, Xia L, Wang L, Wang K, Xiang Y J Cachexia Sarcopenia Muscle. 2025; 16(1):e13717.
PMID: 39871746 PMC: 11773161. DOI: 10.1002/jcsm.13717.
Zhang A, Li Q, Chen Z Int J Mol Sci. 2025; 26(1.
PMID: 39796081 PMC: 11719504. DOI: 10.3390/ijms26010225.
Zhuang K, Wang W, Zheng X, Guo X, Xu C, Ren X Stem Cell Res Ther. 2024; 15(1):438.
PMID: 39563422 PMC: 11575204. DOI: 10.1186/s13287-024-04041-3.
Ma H, Jing Y, Zeng J, Ge J, Sun S, Cui R J Orthop Translat. 2024; 49:23-36.
PMID: 39420945 PMC: 11483279. DOI: 10.1016/j.jot.2024.08.005.